AstraZeneca Business Objects Case Study
1 like1,355 views
AstraZeneca spends over $3 billion annually on research and development across its six international sites. Reducing time-to-market for new drugs is critical as it allows the company to establish brand leadership and generate revenues before generics enter the market. Business Objects business intelligence solutions have provided AstraZeneca visibility into global R&D project data, enabling improved resource utilization, cost control, and the acceleration of drug development timelines. Over 5,000 R&D users can now access information on project schedules, costs and resource usage from a centralized data warehouse. This has provided a competitive advantage by helping AstraZeneca launch products earlier.
AstraZeneca Business Objects Case Study
- 1. 98 AstraZeneca “In this highly competitive business sector, time-to-market dictates brand leadership and revenue generation. Business Objects business intelligence solution has enabled AstraZeneca to improve project management, cost control, and resource utilization, and is helping us achieve competitive research and development timescales.” David Scanlon, Business Manager, AstraZeneca Critical Need to Reduce Time-to-Market AstraZeneca has over 12,000 research and development (R&D) employees across six international sites and spends over $3 billion annually on R&D, the equivalent of over $10 million every working day. Drug development is highly competitive, and each day they saved getting a new brand to market saves millions of dollars. Drug patents last 20-25 years, and it typically takes 8-12 years to bring a drug to market. Therefore, the shorter the product development and clinical trial, the longer a company has to establish brand leadership and generate revenues before a competitor can bring generic products to market. Reduced time-to-market is dependent upon maximizing project management efficiency, resource utilization, and cost control. Immediate access to one consistent view of R&D information is critical to support these processes. “To support our requirement to accelerate drug development, AstraZeneca requires fast and easy access to global R&D information,” says Chris Saxby, IT Consultant, AstraZeneca. Improved Visibility to R&D Data To provide complete visibility of R&D information across the world, AstraZeneca has developed and deployed the Matrix project management system. This system uses BusinessObjects to query and analyze global R&D information stored centrally in an Oracle data warehouse. Over 5,000 users across AstraZeneca's six international R&D sites can access and interrogate information on project schedules, project costs, and resource utilization. In addition, the company has selected BusinessObjects as its standard business intelligence solution, and it is used across other core areas of the business such as manufacturing, finance, and marketing. CHALLENGE 1 To improve visibility and access of global R&D project management information SOLUTION 1 BusinessObjects provides information to over 5,000 R&D users globally 1 BusinessObjects Dashboard Manager will deliver key performance indicators to senior management BENEFITS 1 Global transparency of R&D information 1 Improved resource utilization 1 Tighter cost control 1 Accelerating drug BI STANDARDIZATION United Kingdom
- 2. 99PHAR MACEUTICAL/HEALTHCARE The pharmaceutical giant is also implementing BusinessObjects Dashboard Manager in conjunction with Advizor Solutions technology to deliver dynamic at-a-glance displays that show the status of key performance indicators across R&D to senior management. According to Saxby, “Business Objects solutions are transforming the availability and accessibility of R&D project information within AstraZeneca.” BI Enables Competitive Edge BI solutions from Business Objects enable AstraZeneca to track, understand, and manage the huge volumes of project data that it creates every day. Senior management, development teams, and therapeutic area teams all have instant access to one consolidated view of up-to-date R&D information to help them make faster and more confident decisions. This fast and easy access to R&D data provides a greater global view of project activity and of how much R&D is spending on developing new products. And this R&D insight enables more accurate project scheduling, project budgeting, and resource allocation—helping AstraZeneca to plan more effectively and reduce costs. Leveraging the information provided by BusinessObjects, AstraZeneca is gaining a significant competitive edge by accelerating its time-to-market for new products. A faster development process helps AstraZeneca to launch products earlier in order to secure early brand leadership and increased revenues. Immediate access to R&D information is a critical component in the race to be first-to-market in the pharmaceutical industry. With BusinessObjects, we now have a platform to deliver this information globally in a flexible manner that supports constant innovation and change. As a result, we aim to speed development, better manage costs, and ultimately reduce time-to- market. Productivity is the key industry challenge. About AstraZeneca 1 Activity: Pharmaceuticals 1 Sales figures: $18.849 million 1 Staff: 12,000 in R&D 1 Date founded: 1999 AstraZeneca is one of the world’s leading pharmaceutical companies, engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. AstraZeneca has sales activities in over 100 countries and manufacturing facilities in 19 countries. “ ”